United States Drug Patent 8,129,405: Claim Scope, Expiration, Orange Book Position, and Generic Risk

U.S. Patent No. 8,129,405 protects pharmaceutical combinations containing aclidinium, or a covered aclidinium salt, with a beta-2 adrenergic agonist. Its strongest commercial relevance is the aclidinium bromide/formoterol fumarate combination marketed as Duaklir Pressair for chronic obstructive pulmonary disease. The patent also reaches inhaled formulations and treatment methods involving corticosteroids or phosphodiesterase-4 inhibitors, but those additional elements narrow the claims.

The patent is a combination patent rather than a basic compound patent. It does not cover aclidinium monotherapy, beta-2 agonist monotherapy, or every dual bronchodilator combination. Infringement requires the accused product or treatment to contain the claimed aclidinium component and a beta-2 agonist.

What does U.S. Patent 8,129,405 protect?

The patent protects compositions comprising:

Aclidinium or a covered stereochemical form of aclidinium; and
A beta-2 agonist.

The chemical component in claim 1 is aclidinium in its quaternary ammonium form:

3-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane.

The claim expressly covers an enantiomer, a mixture of enantiomers, or a racemate. It also requires an anion associated with the positively charged nitrogen atom. Aclidinium bromide is the commercially relevant salt.

Claim element	Scope
Active anticholinergic	Aclidinium chemical structure
Stereochemistry	Enantiomers, mixtures, and racemates
Counterion	Any single-negative-charge anion under claim 1; listed anions under claim 3
Combination partner	A beta-2 agonist
Formulation	Broad under claim 1; inhalation narrowed under claims 4 and 5
Carrier	Optional under claim 2; lactose specifically covered by claim 9
Additional actives	Steroid and/or phosphodiesterase-4 inhibitor
Treatment uses	COPD, chronic bronchitis, bronchial hyperreactivity, asthma, and rhinitis

The use of “comprising” makes the independent composition claim open-ended. A product can contain additional active ingredients, excipients, stabilizers, propellants, or device components and still fall within the claim if it contains the required aclidinium and beta-2 agonist elements.

How broad is claim 1 of U.S. Patent 8,129,405?

Claim 1 is the principal broad claim. It does not limit the beta-2 agonist to formoterol, arformoterol, salmeterol, indacaterol, vilanterol, olodaterol, albuterol, or any other named molecule. The generic reference to “a β2 agonist” creates potentially broad coverage across short-acting and long-acting beta-2 agonists.

The claim also does not specify:

A particular aclidinium-to-beta-2 agonist ratio;
A dose strength;
A particle-size distribution;
A device;
A propellant;
A release profile;
A treatment schedule;
A particular patient population; or
A particular beta-2 agonist salt.

The broadest practical infringement theory therefore concerns a finished pharmaceutical composition containing aclidinium and any beta-2 agonist, including an inhaled fixed-dose combination.

The principal limitations are chemical identity and combination structure. A product containing glycopyrrolate, tiotropium, umeclidinium, or another long-acting muscarinic antagonist instead of aclidinium does not satisfy the literal aclidinium limitation.

What do claims 2 through 9 add?

The dependent claims divide the commercial and technical scope into formulation and combination subgroups.

What formulation patents are covered?

Claim 2 requires a pharmaceutically acceptable carrier or diluent. Claim 9 narrows that carrier to lactose, which is significant for dry-powder inhalers because lactose is commonly used as a carrier in inhalation powders.

Claims 4 and 5 focus on inhaled administration:

Claim 4 covers a composition suitable for inhalation.
Claim 5 covers a liquid inhalant, powder inhalant, or inhalation aerosol.

These claims are narrower than claim 1 but more directly aligned with commercial respiratory products. A dry-powder inhaler containing aclidinium and formoterol would be a principal target of claims 1, 4, and potentially 9.

The claims do not expressly require the Pressair device, a particular metering mechanism, or a particular inhaler architecture. Device-specific protection, if any, would normally arise from separate patents.

What additional active ingredients are covered?

Claim 6 adds a steroid. Claims 7 and 8 add a phosphodiesterase IV inhibitor, now generally called a phosphodiesterase-4 inhibitor.

The claim structure covers:

Aclidinium plus beta-2 agonist;
Aclidinium plus beta-2 agonist plus steroid;
Aclidinium plus beta-2 agonist plus PDE-4 inhibitor; and
Aclidinium plus beta-2 agonist plus both a steroid and a PDE-4 inhibitor.

These claims may be relevant to triple or investigational respiratory combinations. They do not require the steroid or PDE-4 inhibitor to be inhaled unless the applicable dependent claim also includes the inhalation limitation through dependency.

Does the patent cover Duaklir Pressair?

Duaklir Pressair contains aclidinium bromide and formoterol fumarate. That product profile falls within the core technical combination described by claim 1 and within the inhalation categories recited in claims 4 and 5. The FDA-approved indication is maintenance treatment of airflow obstruction in patients with COPD. [U.S. Food and Drug Administration, 2019]

Product	Active ingredients	Relationship to U.S. 8,129,405
Duaklir Pressair	Aclidinium bromide/formoterol fumarate	Direct commercial relevance
Tudorza Pressair	Aclidinium bromide	Outside claim 1 because no beta-2 agonist
Bevespi Aerosphere	Glycopyrrolate/formoterol fumarate	Different muscarinic antagonist
Stiolto Respimat	Tiotropium/olodaterol	Different muscarinic antagonist
Anoro Ellipta	Umeclidinium/vilanterol	Different muscarinic antagonist
Trelegy Ellipta	Fluticasone furoate/umeclidinium/vilanterol	Different muscarinic antagonist

The patent therefore has greater relevance to aclidinium combination products than to the broader long-acting bronchodilator market.

What do the method-of-use claims cover?

Claim 10 covers treating:

Chronic obstructive pulmonary disease;
Chronic bronchitis;
Bronchial hyperreactivity;
Asthma; or
Rhinitis.

The method requires administering an effective amount of the composition of claim 1 to a human or animal patient.

Because claim 10 depends on claim 1, the method claim inherits the composition limitations. An accused treatment must involve administration of a composition containing the covered aclidinium structure and a beta-2 agonist. Use of aclidinium alone would not satisfy the claim.

Claims 11 through 13 add administration of a steroid and/or PDE-4 inhibitor. These claims are narrower and may be difficult to assert against a product that contains only aclidinium and a beta-2 agonist.

The method claims create potential inducement theories against a manufacturer if labeling instructs the use of a covered composition for one of the listed diseases. A generic applicant’s proposed labeling and product composition would be central to any Paragraph IV dispute.

When does U.S. Patent 8,129,405 lose exclusivity?

The patent issued on March 6, 2012. Public patent records identify a 2004 priority date for the underlying subject matter. On a standard 20-year patent-term calculation from the earliest effective nonprovisional filing, the nominal expiration falls in 2024 or 2025, depending on the governing priority and filing dates. The controlling date is the expiration date recorded by the USPTO and, for listed drug patents, the FDA Orange Book.

Event	Date or period
Earliest priority period	2004
U.S. patent grant	March 6, 2012
Standard term basis	20 years from the applicable U.S. nonprovisional filing
Expected nominal expiration	2024-2025 range
Possible adjustments	Patent-term adjustment, terminal disclaimer, or patent-term extension

The patent’s commercial blocking value must be separated from its nominal term. A patent can expire while a product remains protected by later formulation, device, process, or regulatory exclusivity rights.

Patent-term adjustment can extend the term beyond the basic calculation. Patent-term extension under 35 U.S.C. §156 is less likely for a combination patent unless the statutory requirements are met and the patent was selected for extension. The FDA Orange Book provides the operative listed-patent information for an approved drug product. [U.S. Food and Drug Administration, 2024; 35 U.S.C. §§154, 156]

What is the Orange Book status of U.S. Patent 8,129,405?

The patent is associated with the aclidinium/formoterol product class and is relevant to the FDA-listed patent estate for Duaklir-type products. Orange Book listing does not determine claim validity or infringement. It determines whether the patent is part of the statutory certification framework for an ANDA applicant.

A generic applicant seeking approval of a product referencing an NDA with listed patents generally must file one of four certifications:

Paragraph I: no patent information has been submitted;
Paragraph II: the patent has expired;
Paragraph III: approval will occur after patent expiration; or
Paragraph IV: the patent is invalid, unenforceable, or will not be infringed.

For a listed combination patent near or beyond its nominal expiration date, Paragraph III may be commercially preferable if the applicant does not want to initiate litigation. Before expiration, a Paragraph IV certification can trigger a 45-day period for the patent holder to sue and, if timely litigation is filed, a potential 30-month stay of approval under the Hatch-Waxman Act. [Drug Price Competition and Patent Term Restoration Act of 1984]

The Orange Book entry should be reviewed together with later patents covering the inhaler, formulation, manufacturing process, or specific product presentation. A single expired combination patent does not establish that an ANDA applicant has an immediate commercial launch path.

Which companies are challenging the patent?

A patent number alone does not establish the existence of a Paragraph IV challenge, ANDA filing, district-court action, or settlement agreement. Publicly available regulatory and litigation records must be matched by:

The reference-listed drug;
The ANDA number;
The certification date;
The patent listed in the certification;
The filing date of any infringement action; and
The terms of any settlement.

No challenge should be treated as confirmed merely because a generic aclidinium/formoterol product has been announced. A Paragraph IV challenge can target one listed patent while leaving later patents unchallenged.

How strong is the patent estate?

The patent has moderate scope for its central combination but limited scope against substitute products.

Strengths

Broad reference to a beta-2 agonist;
Open-ended “comprising” language;
Coverage of aclidinium stereochemical forms;
Coverage of multiple counterions;
Direct relevance to inhaled fixed-dose combinations;
Method claims directed to major respiratory diseases.

Weaknesses

The claims require aclidinium specifically;
The patent does not cover other muscarinic antagonists;
Formulation claims are relatively functional and generic;
The patent does not identify a specific beta-2 agonist in claim 1;
A later entrant may design around the claims by using another long-acting muscarinic antagonist;
Near-term expiration materially reduces enforcement leverage.

Validity defenses could focus on anticipation or obviousness based on earlier disclosures of aclidinium, beta-2 agonists, inhaled respiratory combinations, and treatment of COPD. Enablement and written-description arguments would depend on the breadth of “a beta-2 agonist” and the technical disclosure supporting the full genus.

What generic launch risks exist?

The main launch scenarios are:

Scenario	Commercial consequence
Patent expired and no later blocking patents	ANDA launch may proceed, subject to FDA approval
Paragraph III certification	Approval delayed until the listed expiration date
Paragraph IV certification with timely suit	Potential 30-month approval stay
Later formulation or device patents remain active	Launch may require a design-around or litigation
Settlement with delayed entry	Entry date depends on agreement terms
Product reformulation or different device	May avoid some dependent claims while preserving market access

The patent is most important to a generic applicant developing aclidinium/formoterol. It is much less important to products based on glycopyrrolate, tiotropium, umeclidinium, or other muscarinic antagonists.

Key Takeaways

U.S. Patent 8,129,405 is a combination patent covering aclidinium with a beta-2 agonist.
Claim 1 is broad because it does not name a specific beta-2 agonist and uses open-ended “comprising” language.
Claims 4 and 5 target inhaled liquids, powders, and aerosols.
Claim 9 specifically covers lactose-containing formulations.
Claims 10 through 13 cover treatment of COPD and related respiratory diseases, with optional steroids and PDE-4 inhibitors.
Duaklir Pressair is the primary commercial product associated with the claimed combination.
The patent does not cover aclidinium monotherapy or combinations using a different muscarinic antagonist.
Its nominal term falls in the 2024-2025 period based on the underlying 2004 priority and applicable U.S. term rules.
Orange Book listing and later formulation or device patents must be assessed before determining generic launch freedom.
The patent’s blocking value is strongest for aclidinium/formoterol and weaker against substitute long-acting bronchodilator combinations.

FAQs About U.S. Patent 8,129,405

Does U.S. Patent 8,129,405 cover aclidinium bromide alone?

No. Claim 1 requires aclidinium and a beta-2 agonist. Aclidinium bromide monotherapy falls outside the literal scope of the independent composition claim.

Does the patent cover formoterol fumarate?

It can cover formoterol fumarate when formoterol is combined with the claimed aclidinium component in a pharmaceutical composition. The patent does not independently claim formoterol fumarate.

Does the patent cover triple COPD therapy?

Potentially. Claims 6 through 8 and 11 through 13 add a steroid and/or PDE-4 inhibitor to the aclidinium/beta-2 agonist combination. A triple therapy containing a steroid may fall within claim 6 or claim 11 if all dependency requirements are met.

Can a generic avoid the patent by changing the inhaler device?

Changing the device alone may not avoid claims 1 or 10 because those claims do not require a particular inhaler. Device changes may avoid separate device patents, but they will not remove the aclidinium-plus-beta-2-agonist elements from the composition claims.

Is there biosimilar risk for this patent?

No. Aclidinium and formoterol are small-molecule active ingredients. The relevant regulatory pathway is generally an ANDA or another small-molecule pathway, not a biosimilar application under the Biologics Price Competition and Innovation Act.

References

U.S. Patent No. 8,129,405. (2012). Pharmaceutical compositions comprising aclidinium and a beta-2 agonist. United States Patent and Trademark Office.
U.S. Food and Drug Administration. (2019). Duaklir Pressair prescribing information. FDA.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585.
35 U.S.C. §§ 154, 156.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Spain	9901580	Jul 14, 1999

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1200431	⤷ Start Trial	C300573	Netherlands	⤷ Start Trial
European Patent Office	1200431	⤷ Start Trial	CA 2013 00002	Denmark	⤷ Start Trial
European Patent Office	1200431	⤷ Start Trial	PA2013001	Lithuania	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,129,405

Summary for Patent: 8,129,405